Switzerland· 65472001
Zerbaxa 1.5 g, Pulver für ein Konzentrat zur Herstellung einer Infusionslösung
A ceftolozan und beta-lactamase-inhibitor product containing ceftolozanum, tazobactamum, registered in Switzerland by MSD Merck Sharp & Dohme AG and dispensed under Swissmedic category A. The same ATC class is registered in 11 of our 19 countries.
Checked against Swissmedic (Switzerland) on
Informational only — not a medical device.
Where it is registered
Ceftolozan und beta-lactamase-inhibitor is registered in 11 of 19 countries.
Countries holding a registration under ATC J01DI54 (ceftolozan und beta-lactamase-inhibitor), each read from that country’s own register.
- This record: Switzerland, from Swissmedic (Switzerland)
- 7 of them publish a price we can compare per daily dose
Ceftolozan und beta-lactamase-inhibitor · ATC J01DI54
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
The record
At a glance
Swissmedic (Switzerland)- Active substance
- ceftolozanum, tazobactamum
- Manufacturer
- MSD Merck Sharp & Dohme AG
- Country
- Switzerland (CH)
- ATC code
- J01DI54
- ATC class
- Ceftolozan und Beta-Lactamase-Inhibitor
- Defined daily dose
- 3 g, P
- Swissmedic category
- A
- Reimbursed
- No
- Source register
- Swissmedic (Switzerland)
- Last checked
- September 12, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Ceftolozan und beta-lactamase-inhibitor in 13 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- CanadaZERBAXAMERCK CANADA INC
- CzechiaZERBAXAMerck Sharp & Dohme B.V., Haarlem
- SpainZERBAXA 1 G/0,5 G POLVO PARA CONCENTRADO PARA SOLUCION PARA PERFUSIONMerck Sharp & Dohme B.V.
- FinlandZerbaxaMerck Sharp & Dohme B.V.
- FranceZERBAXA 1 g/0,5 g, poudre pour solution à diluer pour perfusionMERCK SHARP & DOHME (PAYS-BAS)
- United KingdomZerbaxa 1g/0.5g powder for concentrate for solution for infusion vialsMerck Sharp & Dohme (UK) Ltd
- IrelandZerbaxa 1 g/0.5 g powder for concentrate for solution for infusionMerck Sharp & Dohme BV,
- IcelandZerbaxaMerck Sharp & Dohme B.V.*
Authorised across Europe · EMA
The same active substance is authorised in 3 EEA countries. Names it is sold under:
- Iceland · Zerbaxa
- Liechtenstein · Zerbaxa
- Norway · Zerbaxa
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of Swissmedic (Switzerland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/3e20d907-ceb2-4634-9b13-d7d471c768f0 GET /v1/drugs/3e20d907-ceb2-4634-9b13-d7d471c768f0?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"source": "swissmedic_auth",
"heilmittelcode": "Synthetika"
}See everything about ceftolozan und beta-lactamase-inhibitor.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.